Rocket Pharmaceuticals, Inc. (RCKT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Viewpoint - Rocket Pharmaceuticals is a late-stage biotech company focused on developing gene therapies for complex and rare genetic diseases, emphasizing asset selection for conditions that are devastating or fatal, particularly in children [2][3]. Financial Position - As of September 30, 2025, Rocket reported $222.8 million in cash, cash equivalents, and restricted cash, which is expected to fund operations into the second quarter of 2027, excluding any potential sale of a PRV related to the KRESLADI approval anticipated on March 28, 2026 [4]. Business Strategy - The company operates two platforms, AAV and lentiviral, and manages the entire process from discovery to in-house manufacturing, aiming to target medical conditions with a direct mechanism of action and a reasonable market size for business expansion [2][3].